The FDA has issued a warning letter related to BD Pyxis automated medication dispensing systems — technology that was part of ...

There has been no shortage of news covered across the diabetes and drug delivery markets over the course of 2024.

Abbott (NYSE:ABT) reached an agreement with Dexcom (Nasdaq:DXCM) to settle all outstanding patent disputes between companies.

Vivani Medical (Nasdaq:VANI) announced today that it initiated screening and enrollment for a first-in-human trial of its GLP ...

Dexcom (Nasdaq:DXCM) announced today that it launched a proprietary generative AI platform integrated with its glucose ...

Eli Lilly (NYSE:LLY) announced today that the Egyptian Drug Authority approved insulin glargine manufactured in partnership ...

Abbott and Dexcom are two leaders in the continuous glucose monitoring (CGM) space. They offer market-leading platforms, with ...

Qnovia announced that it raised $16 million in Series B funding to support its inhaled smoking cessation therapy platform.

Embecta (Nasdaq:EMBC) filed with the state of Massachusetts to confirm a workforce reduction affecting 118 employees.

MannKind today announced six-month results from its Phase 3 INHALE-1 study of Afrezza insulin inhalation powder in children.

The FDA said Fresenius Kabi told customers to remove its Ivenix large-volume infusion pumps from use for repair.

[Image courtesy of Dexcom/Oura] Oura announced today that it completed a $200 million Series D funding round that included Dexcom (Nasdaq:DXCM). The investment comes as part of a new health monitoring ...